Loading...

CNTA CENTESSA PHARMACEUTICALS PLC Product Launches 8-K Filing

CNTS

CNT

CENTESSA PHARMACEUTICALS PLC

(CNTA)

2024 8-K

Show Summary

Summary

Product Expansion

Financial Statements

Financial Results

License Agreement

Investor Update

Financial Results

Positive Clinical Data

Financial Results

Annual General Meeting

Appointment of Chief Financ...

Financial Results Announcement

Underwriting Agreement

FDA Clears IND for Phase 1 ...

Financial Results Announcement

Investor Conferences

Investor Conferences

Data Presentation and Press...

Financial Results Announcement

Abstract Release

Financial Results and Prese...

Investor Conferences

Regulation FD Disclosure

Financial Results Announcement

Financial Results and Prese...

Sales Agreement with SVB Se...

FDA Clearance of IND Applic...

External Links:

Centessa Pharmaceuticals announced positive interim Phase 1 clinical data for its orexin agonist, ORX750, showing significant improvements in wakefulness and sleep latency in sleep-deprived volunteers, with favorable safety results.

AI Assistant

CENTESSA PHARMACEUTICALS PLC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.